secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bioventus Inc. (BVS)
CIK:        0001665988
Form:       8-K/A
Filed at:   2022-11-21T23:59:59+00:00
Accession:  0001628280-22-030565
Event type: earnings
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bioventus amends Q3 results with $189M impairment; cuts FY2022 guidance
-----------------------------------------------------------------------

- Net loss of $145.7M ($1.76 loss per share) vs $2.3M loss in prior year; includes $189.2M non-cash impairment.
- Net sales of $128.7M, +18.2% YoY; organic sales down 0.5%.
- FY2022 guidance cut: net sales now $517-522M (prev $547.5-562.5M); Adj. EBITDA $75-79M (prev $94-104M).
- Non-GAAP EPS guidance lowered to $0.20-0.25 from $0.47-0.57.
- Company discontinued development of MOTYS drug candidate.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1665988/000162828022030565/0001628280-22-030565-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1665988/000162828022030565/bvs-20221108.htm
  HTML page:      https://secwatch.observer/filing/0001628280-22-030565

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer